Vega Therapeutics

Vega Therapeutics is a clinical-stage biotechnology company developing novel therapies for rare blood disorders, addressing unmet patient needs in these neglected conditions, starting with von Willebrand Disease (VWD). The company’s lead candidate, VGA039, is the first dedicated antibody therapy for VWD, featuring a novel mechanism of action targeting protein S. By attenuating the protein S cofactor functions of tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), VGA039 enhances and restores thrombin generation during the initiation and propagation phases of coagulation, addressing the fundamental mechanisms of clot formation in VWD. VGA039 has the potential to become a universal hemostatic therapy capable of treating a variety of bleeding disorders.